Mass drug administration coverage evaluation for lymphatic filariasis in selected endemic districts of Jharkhand, India
Transactions of The Royal Society of Tropical Medicine and Hygiene · 2025
DOI: 10.1093/trstmh/trae136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, 2025. Verfasst von Bijit Biswas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community & Family Medicine, All India Institute of Medical Sciences, Deoghar, Jharkhand, India. Hauptthemen laut MEDLINE: Elephantiasis, Filarial, Mass Drug Administration, Filaricides, Endemic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Centre for Vector Borne Diseases Control.
Abstract (Originalsprache)
Background
This study aimed to evaluate mass drug administration (MDA) coverage for lymphatic filariasis (LF) in selected endemic districts of Jharkhand, India, and to identify household-level determinants of drug consumption.
Methods
A cross-sectional coverage evaluation survey was conducted in the Deoghar, Giridih and Godda districts of Jharkhand in 2023 within 6 wk of the completion of the MDA campaign. The survey included 9039 individuals from 1680 households across 56 randomly selected clusters (three urban, eight tribal and 45 rural).
Results
Approximately 78.5% of households reported that at least one member consumed MDA drugs, with 54.5% reaching ‘complete epidemiological drug coverage’. Factors positively associated with achieving ‘complete epidemiological drug coverage’ included higher education levels (adjusted OR [AOR] 1.02), awareness of LF (AOR 2.32), prior communication about MDA (AOR 1.38) and previous MDA participation (AOR 4.42). By contrast, larger family sizes were associated with a lower likelihood of achieving complete coverage (AOR 0.78). Adverse events were experienced by 14.9% of participants, primarily when MDA drugs were consumed on an empty stomach. Key reasons for non-compliance included perceived absence of disease (25.5%), fear of side effects (22.4%) and absence during the campaign (20.9%).
Conclusions
MDA coverage was suboptimal, with only one-half of households achieving ‘complete epidemiological drug coverage’. Enhancing MDA coverage and compliance requires intensified Information, Education, and Communication efforts, especially among marginalized communities, both during campaigns and all year round.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Community & Family Medicine, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
- Department of Microbiology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
- Department of General Surgery, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
- Executive Director & Chief Executive Officer, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
ORCID-Profile: Bijit Biswas
Förderung
- National Centre for Vector Borne Diseases Control
Zitieren
APA
Biswas, B., Gupta, P., Jahnavi, G., Ranjan, N., Patra, S. R., & Varshney, S. (2025). Mass drug administration coverage evaluation for lymphatic filariasis in selected endemic districts of Jharkhand, India. Transactions of The Royal Society of Tropical Medicine and Hygiene. https://doi.org/10.1093/trstmh/trae136
Vancouver
Biswas B, Gupta P, Jahnavi G, Ranjan N, Patra SR, Varshney S. Mass drug administration coverage evaluation for lymphatic filariasis in selected endemic districts of Jharkhand, India. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2025. doi:10.1093/trstmh/trae136
BibTeX
@article{Biswas2025,
author = {Biswas, Bijit and Gupta, Pratima and Jahnavi, G and Ranjan, Nishit and Patra, Satya Ranjan and Varshney, Saurabh},
title = {Mass drug administration coverage evaluation for lymphatic filariasis in selected endemic districts of Jharkhand, India},
journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
year = {2025},
doi = {10.1093/trstmh/trae136}
}
EUVIMED